TMEM240 and breast carcinoma: Circulating methylated TMEM240 dramatically and gradually decreases and then diminishes in patients with various subtypes of breast cancer who do not show disease progression (Fig. 5), suggesting that measurement of circulating methylated TMEM240 could be used to detect the presence of residual disease.